Equities analysts expect that Johnson & Johnson (NYSE:JNJ) will report $1.98 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Johnson & Johnson’s earnings, with estimates ranging from $1.86 to $2.10. Johnson & Johnson reported earnings of $2.12 per share during the same quarter last year, which indicates a negative year over year growth rate of 6.6%. The firm is scheduled to announce its next quarterly earnings report before the market opens on Tuesday, October 13th.
On average, analysts expect that Johnson & Johnson will report full year earnings of $7.85 per share for the current year, with EPS estimates ranging from $7.75 to $7.95. For the next year, analysts expect that the company will report earnings of $8.94 per share, with EPS estimates ranging from $8.48 to $9.45. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. During the same quarter in the previous year, the business earned $2.58 EPS. The business’s quarterly revenue was down 10.8% compared to the same quarter last year.
A number of analysts have commented on JNJ shares. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $161.00 to $164.00 in a report on Monday, July 20th. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Raymond James lifted their price target on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $163.00.
JNJ traded down $1.08 during trading on Monday, reaching $146.24. 5,485,602 shares of the company’s stock were exchanged, compared to its average volume of 8,360,347. The company’s fifty day moving average price is $149.19 and its 200-day moving average price is $144.96. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm has a market capitalization of $385.02 billion, a PE ratio of 21.38, a P/E/G ratio of 3.29 and a beta of 0.68.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a $1.01 dividend. The ex-dividend date was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
A number of large investors have recently modified their holdings of JNJ. Sofos Investments Inc. lifted its position in Johnson & Johnson by 172.0% during the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock worth $33,000 after buying an additional 726 shares in the last quarter. Altshuler Shaham Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth about $35,000. Lake Point Wealth Management lifted its position in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after buying an additional 169 shares in the last quarter. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth about $42,000. Finally, FAI Wealth Management lifted its position in Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares in the last quarter. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.